The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Vaxess Technologies
Vaxess study highlights GLP-1 delivery with microarray patch
Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs. It features a soluble microarray with tips that gradually dissolve […]
Vaxess raises $9M to support drug delivery patch, GLP-1 work
Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding. Participants in the latest funding round for Woburn, Massachusetts-based Vaxess included RA Capital Management and Engine Ventures. The company plans to use the funds to continue to advance its work in GLP-1 therapeutics and to expand manufacturing capabilities. It […]
Vaccine patch maker Vaxess raises $12M, names new CEO
Shelf-stable vaccine patch maker Vaxess Technologies announced today that it raised $12 million and appointed Rachel Sha as its new CEO. This round brings the company’s total funding to more than $90 million after it raised $9 million last September as well. Investors included RA Capital Management, Engine Ventures, GHIC and Mission Bio Capital. Cambridge, […]
Vaxess raises $9M to support shelf-stable vaccine patch
Vaxess Technologies announced today that it raised an additional $9 million in venture capital funding to support its vaccine delivery technology. Cambridge, Massachusetts-based Vaxess develops a shelf-stable vaccine patch with the potential for self-application. The company’s MiMix system features sustained-release technology for administering vaccines and therapeutics. For vaccines, its controlled release simulates the pace of […]
Vaccine patch maker Vaxess names former Sanofi exec as chief strategy officer
Vaxess Technologies, developer of a shelf-stable vaccine patch, announced today that it named Steve Bende as its new chief strategy officer. Bende previously served as global head of new products at Sanofi Pasteur. He led international, multifunctional teams at the pharmaceutical giant. That included assessing the commercial viability of potential new products. Prior to Sanofi, […]
Interim data supports Vaxess shelf-stable flu vaccine patch
Vaxess Technologies today announced positive interim results from a first-in-human trial of its influenza vaccine patch. Cambridge, Massachusetts-based Vaxess evaluated VX-103, a monovalent seasonal influenza vaccine patch. The trial included 45 healthy patients and evaluated the H1N1 influenza antigen from Vaxess’ partner, GC Biopharma. Delivery of the vaccine took place through the Vaxess Mimix patch. […]
Vaxess Technologies raises $2M for its silk-based vaccine delivery through the skin
Vaxess Technologies today filed an SEC Form D to confirm the sale of $2 million in debt, options, warrants or other rights to buy securities. According to the filing, three investors contributed to the new notice offering, which made its first sale on Monday, March 22, 2021, before reaching its total offering amount of $2 […]
Vaxess Technologies lands $6m for microneedle vaccines
Vaxess Technologies said today that it won 2 grants from the Bill & Melinda Gates Foundation totalling up to $6 million for the development of inactivated polio and live attenuated measles rubella vaccines using the company’s Mimix sustained-release microneedle patch technology. The company’s Mimix technology is designed for sustained, transdermal delivery of vaccines and inmmunotherapies, […]
